- Memorial Sloan-Kettering has received a $90 million donation as a share of an unprecedented $540 million gift from the Ludwig Cancer Research organization, to 6 prestigious academic institutions. Memorial will use the funds to support research in immuno-oncology – fighting cancer using the immune system.
- MSKCC’s Dr. Michael Mauro is pleased that the FDA is allowing sale of the leukemia drug, Iclusig, to resume after it had been taken off the market.
- Dr. Tim Ahles of MSKCC commented on the phenomenon of premature aging in adult survivors of childhood cancers.